Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2008 Sep 16;99(6):974-7.
doi: 10.1038/sj.bjc.6604624.

An evaluation of the polymorphisms Ins16bp and Arg72Pro in p53 as breast cancer risk modifiers in BRCA1 and BRCA2 mutation carriers

A Osorio  1 , M Pollán, G Pita, R K Schmutzler, B Versmold, C Engel, A Meindl, N Arnold, S Preisler-Adams, D Niederacher, W Hofmann, D Gadzicki, A Jakubowska, U Hamann, J Lubinski, A Toloczko-Grabarek, C Cybulski, T Debniak, G Llort, D Yannoukakos, O Díez, B Peissel, P Peterlongo, P Radice, T Heikkinen, H Nevanlinna, P L Mai, J T Loud, L McGuffog, A C Antoniou, J Benitez; CIMBA
Affiliations
Multicenter Study

An evaluation of the polymorphisms Ins16bp and Arg72Pro in p53 as breast cancer risk modifiers in BRCA1 and BRCA2 mutation carriers

A Osorio et al. Br J Cancer. .

Abstract

The close functional relationship between p53 and the breast cancer susceptibility genes BRCA1 and BRCA2 has promoted the investigation of various polymorphisms in the p53 gene as possible risk modifiers in BRCA1/2 mutation carriers. Specifically, two polymorphisms in p53, c.97-147ins16bp and p.Arg72Pro have been analysed as putative breast cancer susceptibility variants, and it has been recently reported that a p53 haplotype combining the absence of the 16-bp insertion and the presence of proline at codon 72 (No Ins-72Pro) was associated with an earlier age at the onset of the first primary tumour in BRCA2 mutation carriers in the Spanish population. In this study, we have evaluated this association in a series of 2932 BRCA1/2 mutation carriers from the Consortium of Investigators of Modifiers of BRCA1 and BRCA2.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Antoniou AC, Goldgar DE, Andrieu N, Chang-Claude J, Brohet R, Rookus MA, Easton DF (2005) A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes. Genet Epidemiol 29: 1–11 - PubMed
    1. Baynes C, Healey CS, Pooley KA, Scollen S, Luben RN, Thompson DJ, Pharoah PD, Easton DF, Ponder BA, Dunning AM (2007) Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk. Breast Cancer Res 9: R27. - PMC - PubMed
    1. Biros E, Kohut A, Biros I, Kalina I, Bogyiova E, Stubna J (2002) A link between the p53 germ line polymorphisms and white blood cells apoptosis in lung cancer patients. Lung Cancer 35: 231–235 - PubMed
    1. Burkett KG, McNeney BJ (2006) Software for likelihood inference of trait associations with SNP haplotypes and other attributes. J Stat Soft 16: 1–9 - PubMed
    1. Chenevix-Trench G, Milne RL, Antoniou AC, Couch FJ, Easton DF, Goldgar DE (2007) An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). Breast Cancer Res 9: 104. - PMC - PubMed

Publication types